Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'

The CEO's remarks suggest a growing unease within the pharmaceutical sector regarding the sustainability of drug pricing amidst regulatory changes. As the industry grapples with the implications of these policies, it may lead to increased scrutiny over pricing strategies and a reevaluation of market approaches. The next 18 months will be crucial in determining how these policies will reshape the landscape of drug pricing and access in the U.S.